Tech Company Financing Transactions
Sensei Biotherapeutics Funding Round
Sensei Biotherapeutics closed a $28.5 million venture capital round on 10/13/2020. Investors included Cambrian Ventures, H&S Ventures and Apeiron Holdings.
Transaction Overview
Company Name
Announced On
10/13/2020
Transaction Type
Venture Equity
Amount
$28,500,000
Round
Undisclosed
Investors
Proceeds Purpose
Sensei will use some of the money to expand development of SNS-301, a bacteriophage engineered to express a fusion protein of native bacteriophage GPD protein and a selected domain of aspartate ß-hydroxylase (ASPH).
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1405 Research Blvd. 125
Rockville, MD 20850
USA
Rockville, MD 20850
USA
Phone
Website
Email Address
Overview
Sensei Biotherapeutics is a clinical-stage biotechnology company developing novel biologics therapies targeting key components of the immune system for the treatment of cancers of unmet need. Driven by innovative science, world class scientists, and an entrepreneurial culture.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Celebi
Chief Medical Officer
Marie Fjaellskog
Chief Scientific Officer
Robert Pierce
Vice President
Jean Campbell
Vice President
Edward van der Horst
VP - Finance
Erin Colgan
VP - Operations
Pauline Callinan
VP - Operations
Alice Drumheller
Browse more venture capital transactions:
Prev: 10/13/2020: YotaScale venture capital transaction
Next: 10/13/2020: Clair venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC transactions reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs